A lung cancer precision medicine trial

VOLUME 28 | SUMMER 2025

NEWSLETTER

WWW.LUNG-MAP.ORG

S1900E Results Presented at ASCO

Primary results from the Lung-MAP S1900E substudy were presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) earlier this summer.

S1900E looked at how co-mutations in tumor suppressor genes affect the efficacy of the drug sotorasib in treating *KRAS* G12C-mutated non-small cell lung cancer (NSCLC).

The study team hypothesized that co-mutations would not affect sotorasib's efficacy.
Study Cohort 1 – patients



with a *TP53* co-mutation – and Cohort 3 – co-mutations in other genes (or no comutations) – met this endpoint.

Based on results from Cohort 2, however, the abstract's authors conclude that co-mutations in *STK11* have a detrimental effect on sotorasib's efficacy in treating *KRAS* G12C-mutated NSCLC. Read the abstract.

COMING IN SEPTEMBER: S1900J Revision Expands Testing Options, Eligibility

A revision to sub-study S1900J (amivantamab hyaluronidase for MET amplification) is CTEP-approved and expected to activate mid-September.

The revision will expand testing options (now limited to Foundation Medicine testing) to include the full range of NGS platforms accepted for Lung-MAP 3.0.

The revised eligibility criteria will also allow *KRAS*-activating mutations other than the *KRAS* G12C mutation.

If your site has not previously opened <u>\$1900</u>J, the September revision is a great reason to revisit the sub-study!

Key Takeaway Points

1

Lung-MAP S1900E
utilized rigorous
biomarker definitions
to prospectively
examine the effect of
co-mutations (co-mut)
on sotorasib in KRAS
G12C NSCLC.

2

In Lung-MAP S1900E, STK11 co-mut cohort had lower efficacy with sotorasib than observed in TP53 or OTHER co-mut cohort.

Important to factor in co-mutations in KRAS G12C NSCLC when anticipating outcomes to KRAS G12C inhibitors.

LEARN MORE AT WWW.LUNG-MAP.ORG

















A lung cancer precision medicine trial

A Lung-MAP Advocacy Webinar

The Lung-MAP team held a May webinar to update the lung cancer advocacy community on the trial's recent evolution and to learn from them about emerging patient needs. More than 300 people tuned in for the event.

Drs. Karen Reckamp and Saiama Waqar, Lung-MAP's chair and vice-chair, presented on the current state of the trial, and S1900K chair, Dr. Paul Paik, gave an update on that substudy.

Dr. Bryan Faller, of Missouri
Baptist Medical Center,
provided a community
clinician's perspective
on conducting LungMAP. He spoke of
the benefits of trial
participation for rural
patients and related
the experience of one
patient at a rural site
whose treatment on
sub-study S1800D led
to a remission that, at
the time of the webinar,

had extended for almost three years (and counting).

At the core of the session was a panel discussion with leaders from several lung cancer advocacy organizations. Here are some of the key messages that emerged:

- Comprehensive biomarker testing at diagnosis is now critical in guiding personalized treatment for nonsmall cell lung cancer and should be available to all patients.
- Clinical trials should be integrated into standard cancer treatment pathways,

- so that trial participation is considered even at the earliest stages of treatment.
- External barriers to trial participation – logistical, financial, informational – need to be lowered, and steps such as decentralized trial designs and enhanced patient navigation services may help.
- Broader, more intensive collaboration among advocacy organizations, researchers, and policymakers will accelerate research progress and drive more effective treatments.





A lung cancer precision medicine trial

Site Coordinators Committee: A New Chair


Stephanie Reyes, RN, MSN, OCN, who has chaired the Lung-MAP site coordinators committee (SCC) for the last four years, is stepping down from that leadership position.

Stepping up is Maya Agosto, BA, CCMA, CPT, clinical research coordinator with the Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Bluffton (SC) Campus.

Agosto will move fully into

the role at SWOG's fall group meeting in Chicago. She says one of her key goals will be to foster greater collaboration and knowledge-sharing among site coordinators everywhere who work on Lung-MAP.

Lung-MAP's SCC brings together clinical research professionals and nurses who represent the broad range of skills and expertise needed for effective trial administration



and data management.
The committee provides
feedback to and from LungMAP leadership to enhance
accrual and improve study
management.

Tips & Tricks: Helping Staff Order the Right NGS Test

Some site coordinators have found that tissue submitted for LUNGMAP testing using their site's preferred NGS platform has had a less comprehensive genomic panel run on it because that is the default panel used by their institution. The outcome is test results that can't be used for Lung-MAP sub-study assignment.

This may be a particular risk at institutions that contract with an outside provider for pathology services, or when a patient gets a biopsy at a remote site.

Helping your staff avoid inadvertently submitting a sample for an insufficient panel may require some re-education.

LUNGMAP NGS Testing Reference Page
Approved Commercial and Academic Laboratories
As of [7/18/2025]

Approved tissue-based NGS testing laboratories include:
Commercial Laboratories

- Boston/Gene (Tumor Potrail Test)
- Boston/Gene (Tumor Potrail Test)
- Caris Life Sciences (MI Tumor Seek Hybrid)
- Caris Life Sciences (MI Tumor Seek Hybrid)
- Caris Life Sciences (MI Tumor Seek Hybrid)
- Foundation Medicine (Foundation/One CDx)
- Foundation Medicine (Foundation/One CDx)
- Genomic Testing Cooperative (Soil Tumor Profile)
- The Jackson Laboratory (SOMASEQ)
- Laborop Oncology (OmniSeq INSIGHT)
- Myriad Genetics (Precise Tumor)
- NeoGenomics Laboratories (Neo Comprehensive - Solid Tumor)
- Path/Group (SmarfGenomics Complete)
- Personal Genome Diagnostics (eilor Tissue Complete)
- Personal Genome Diagnostics (eilor Tissue Complete)
- Paradigm Diagnostics Informatics (#Portolio, Comprehensive NGS)
- Strata Oncology (Strata Select)
- Tempus (xT Solid Tumor)

Academic Laboratories:

- Augusta University
- Bigham and Women's Hospital
- Cedar-Sinial Medical Center
- Chulmbis University
- Chilase Clancer Center
- Courbis University
- Danie-Taber Cancer Lenter
- Courbis University
- Danie-Taber Cancer Center

Consider talking to the site liaison from your preferred NGS platform. They may be available to provide in-service training to help clarify which test(s) should be ordered at disease progression for

patients enrolled to LUNGMAP.

They can also outline the steps in their platform's submission process and review the resources and services they provide. For example, site staff may be able to use an NGS platform's own portal to submit Lung-MAP requisitions directly.

Finally, if you do find yourself with NGS test results that are not usable for Lung-MAP, remember that Foundation Medicine testing is still a nocost option (assuming sufficient tissue remains or a biopsy can be performed).

The current list of acceptable NGS tests is linked from the Lung-MAP Resources page.


Pragmatica-Lung Reports Out at ASCO

Two abstracts with key Pragmatica-Lung (S2302) results were presented at the 2025 ASCO Annual Meeting in June.

This trial was the phase III follow-on to Lung-MAP S1800A. Unlike that sub-study, however, Pragmatica-Lung did *not* find an overall survival benefit from the combination of ramucirumab plus pembrolizumab compared to standard of care treatment in patients with advanced NSCLC.

Overall survival was similar on both arms, so the combination may offer some patients a non-chemotherapy option with fewer toxicities. And a pre-specified subset analysis suggests there may be a survival benefit for patients whose disease has squamous cell histology, but longer-term follow-up data are needed to see whether such a benefit truly emerges.

Lung-MAP Update Forum, Friday, September 19:



You're Invited

The Lung-MAP Update Forum at the SWOG group meeting will be accessible via Zoom.

Tune in to learn the latest on where Lung-MAP is and where it's headed!

Friday, September 19, 4:15 - 5:45 pm CT

Where Pragmatica-Lung succeeded spectacularly was in demonstrating a model for streamlined, pragmatic studies that are

- Developed, activated, and conducted more rapidly
- Easier for sites to open, conduct, and enroll to
- Accessible to a broader range of patients, allowing enrollment of a group of


participants highly representative of the larger population of patients

There's plenty more to learn from the ASCO abstracts about Pragmatica-Lung's results and impact: https://meetings.asco.org/abstracts-presentations/247054.

Sub-Study Summaries for Site Staff

For sub-studies S1800E and S1900K, the CTSU has posted Protocol Summary Sheets, two-page PDFs designed as quick reference resources for staff. They replace the former Physician Fact Sheets and Protocol Cards (which are still available for S1900G).

You can find the *Protocol Summary Sheet* listed under the "Protocol Related Documents" tab on a sub-study's CTSU.org page. Or just follow the links at right. The S1900J edition will soon be posted as well.



Lung-MAP Enrollment Leaders

Congratulations and heartfelt thanks to the following sites and investigators, leaders in patient enrollment to LUNGMAP from August 2024 through July 2025!

TOP-ACCRUING SITES TO LUNGMAP LAST 12 MONTHS (AUG 2024 – JULY 2025)

Palo Alto Medical Foundation-Sunnyvale	Sunnyvale, CA	18
Edwards Comprehensive Cancer Center	Huntington, WV	15
Sutter Pacific Medical Foundation	Santa Rosa, CA	13
Harold Alfond Center for Cancer Care	Augusta, ME	10
University of Kansas Hospital-Westwood Cancer Center	Westwood, KS	8
Mercy Hospital South	Saint Louis, MO	7
Saint Mary's Medical Center	Huntington, WV	7
University of New Mexico Cancer Center	Albuquerque, NM	7
UPMC Hillman Cancer Center – Monroeville	Monroeville, PA	7
Eastern Maine Medical Center Cancer Care	Brewer, ME	6
Palo Alto Medical Foundation Health Care	Palo Alto, CA	6
Ralph H Johnson VA Medical Center	Charleston, SC	6
Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay, WI	6

TOP-ACCRUING INVESTIGATORS TO LUNGMAP LAST 12 MONTHS (AUG 2024 – JULY 2025)

Kim-Son Nguyen	Palo Alto Medical Foundation-Sunnyvale	11
Zeyad Kanaan	Sutter Pacific Medical Foundation	11
Chao Huang	U Kansas Hosp-Westwood Ca Ctr & Kansas City VAMC	9
Toni Pacioles	Edwards Comprehensive Cancer Center	8
Moises Harari-Turquie	University of New Mexico Cancer Center	6
Muhammad Omer Jami	l Edwards Comprehensive Cancer Center	6
Oleksandra Lupak	Ralph H Johnson VA Medical Center	6
David Groteluschen	Saint Vincent Hospital Cancer Cntr at Saint Mary's	4
Gauri Kiefer	UPMC Cancer Centers - Arnold Palmer Pavilion	4
Tianhong Li	Mather VA Medical Ctr & UC Davis CCC	4
Huy Nguyen	Palo Alto Medical Foundation-Sunnyvale	4
Nishant Tageja	UPMC Hillman Cancer Center – Monroeville	4

* (*)		
AS OF AUGUST 24, 2025, LUNGMAP HAS LOGGED:		
3,715	screening registrations	
1,955	sub-study assignments	
524	sub-study registrations	

SITES ENROLLING FIRST PATIENT SINCE LAST NEWSLETTER (MAY 12, 2025)

Congratulations to the following sites, which have recently enrolled their first patient(s) to LUNGMAP!

- •Baptist Cancer Cntr-Grenada (MS)
- •Baptist Memorial Hospital and Cancer Center-Collierville (TN)
- •Dartmouth Cancer Cntr North (VT)
- •Huntsman Cancer Institute/ University of Utah (UT)
- •Kaiser Permanente-Caton Hill Medical Center (VA)
- •Mather Veteran Affairs Medical Center (CA) (enrolled 4!)
- •Memorial Hospital East (IL)
- •Memorial Sloan Kettering Basking Ridge (NJ)
- •Providence Portland Medical Center (OR)
- •Ridley-Tree Cancer Center (CA) (enrolled 3!)
- •Saint Francis Medical Center (MO)
- •Siteman Cancer Center-South County (MO)
- •U of Virginia Cancer Center (VA)
- •VA Palo Alto Health Care System (CA)

CONTACT US

Request Review of New NGS Test LungmapNGS@swog.org
General Medical Questions LUNGMAP@swog.org
Protocol & Regulatory Questions jbeeler@swog.org
Eligibility & Data Submission Questions LUNGMAPQuestion@crab.org
Central Monitoring Questions centralmonitorquestion@crab.org
Quality Assurance Auditing Questions qamail@swog.org

Funding Questions funding@swog.org

S1800E Study Chairs S1800EMedicalQuery@swog.org

S1900G Study Chairs S1900GMedicalQuery@swog.org

S1900J Study Chairs S1900JMedicalQuery@swog.org

S1900K Study Chairs <u>S1900KMedicalQuery@swog.org</u>